Top Markets
#1 EXOD EXOD +56.80%
#2 Glidr Glidr +35.94%
#3 Fabric Protocol Fabric Protocol +22.59%
#4 Nockchain Nockchain +21.22%
#5 Bedrock Bedrock +19.36%
#6 Cysic Cysic +17.50%
#7 Perle Perle +13.36%
#8 The Black Bull The Black Bull +11.48%
#9 Tutorial Tutorial +8.58%
#10 Epic Chain Epic Chain +7.04%
Coin of the day
EXOD EXOD
設定
言語
日本
通貨
USD
テーマ
BerGenBio ASA BerGenBio ASA

BerGenBio ASA

BGBIO
株式のランク #37880
BerGenBio ASA is a biopharmaceutical firm in the clinical development stage,... BerGenBio ASA is a biopharmaceutical firm in the clinical development stage, focused on developing therapies for drug-resistant, immune-evasive, and metastatic cancers, in addition to respiratory conditions. Its leading compound, Bemcentinib, is a bio-available small molecule AXL inhibitor currently in Phase II clinical trials for major cancer indications and COVID-19. The Phase II trial program specifically addresses non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Moreover, the company is progressing tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials. BerGenBio ASA also maintains a collaboration agreement with Merck & Co. for its clinical studies. The company was founded in 2007 and operates from its base in Bergen, Norway.
株価
$0.051239
最終同期: 2025-11-24
時価総額
$1.38M
変化（1日）
-4.48%
変化（1年）
-54.57%
国
NO
取引 BerGenBio ASA (BGBIO)

カテゴリー

Healthcare
BerGenBio ASA（BGBIO）のEPS
2026 時点のEPS TTM: 0
BerGenBio ASAの最新の財務報告と株価によると、同社の現在のEPS（TTM）は0です。2026年末には、EPSは0で、2026年のEPS0と同等でした。
BerGenBio ASAのEPS履歴（2026から2026まで）
各年末時点のEPS
年 EPS 変化
提供された日付のデータは十分ではありません。
同様の企業または競合他社のEPS
企業 EPS EPSの差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $13.70 -
BE